JAGX (Jaguar Health) GF Value : $0.00 (As of Apr. 04, 2025)

View and export this data going back to 2015. Start your Free Trial

What is Jaguar Health GF Value?

As of today (2025-04-04), Jaguar Health's share price is $4.57. Jaguar Health's GF Value is $0.00. Therefore, Jaguar Health's Price-to-GF-Value for today is . Based on the relationship between the current stock price and the GF Value, GuruFocus believes Jaguar Health is Not Valued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

Jaguar Health (NAS:JAGX) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) A sufficient margin of safety exists only when the stock is undervalued.

Jaguar Health's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	4.57	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jaguar Health GF Value Related Terms

Thank you for viewing the detailed overview of Jaguar Health's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Jaguar Health Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jaguar Health Inc (NAS:JAGX) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Pine Street, Suite 400, San Francisco, CA, USA, 94104

Website

http://www.jaguar.health

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Executives

Anula Jayasuriya	director	5150 EL CAMINO REAL, SUITE #A-32, LOS ALTOS CA 94022
Pravin R Chaturvedi	officer: Chief Scientific Officer	C/O JAGUAR HEALTH INC., 200 PINE STREET, SUITE 400, SAN FRANCISCO CA 94104
Lisa A Conte	director, officer: CEO & President	213 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Carol R. Lizak	officer: Chief Accounting Officer	201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
James J Bochnowski	director	C/O DELPHI VENTURES, 160 BOVET RD, SUITE 408, SAN MATEO CA 94402
Jonathan S. Wolin	officer: Chief of Staff, CCO & GC	201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Jonathan B. Siegel	director	C/O KINGDON CAPITAL MANAGEMENT, L.L.C., 152 WEST 57TH STREET, 50TH FLOOR, NEW YORK NY 10019
Bryan Ezralow 1994 Trust Dated December 22, 1994	10 percent owner	23622 CALABASAS ROAD, SUITE 200, CALABASAS CA 91302
Bryan Ezralow	10 percent owner	THE EZRALOW CO, LLC, 23622 CALABASAS ROAD, SUITE 200, CALABASAS CA 91302-1549
Nantucket Investments Ltd	10 percent owner	PO BOX 282, REGENCY COURT, GLATEGNY ESPLANADE, ST PETER PORT Y7 GY1 3RH
Jonathan M Glaser	10 percent owner	11601 WILSHIRE BLVD., SUITE 2180, LOS ANGELES CA 90025
Murray David Macnaughtan	director	C/O JAGUAR HEALTH, INC., 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Greg J Divis	director	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Jeffery C. Johnson	director	C/O SAGARD CAPITAL PARTNERS, L.P., 280 PARK AVENUE, 3F WEST, STAMFORD CT 06901
Sagard Capital Partners, L.p.	10 percent owner	280 PARK AVENUE, 3RD FLOOR WEST, NEW YORK NY 10017